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Covid-19 is a disease resulting from the infection caused by virus SARS-CoV-2. This infection can
have as its product "an excessive and aberrant host immune response", associated with what is
defined as a "cytokine storm" [1]. This storm is characterized "by the plasma increase of many
cytokines that produce long-term damage and fibrosis of lung tissue" [1]. 
Among the cytokines, there is the Interleukin 6 (IL-6), produced by a variety of cell  types and
involved  in  various  physiological  processes  [1].  "Elevated  tissue  and serum levels  of  IL-6  are
implicated in the pathogenesis of various inflammatory and autoimmune disorders including many
forms of rheumatic diseases; they are also implicated in the cytokine release syndrome (CRS)" [1].
As told by Perrone F. et al. in [1], Chinese researchers (Xiaoling Xu et al., Effective Treatment of
Severe COVID-19 Patients with Tocilizumab. ChinaXiv: 202003.00026v1 [2,3]) disclosed that 21
patients with severe or critical COVID-19 pneumonia were treated with a drug, the tocilizumab,
with a reduction of oxygen requirement and other positive results. "These results are considered by
the Chinese authors to be very positive".
Ref.1 is the first protocol in Italy about cytokine storm and the use of the Tocilizumab drug. The
main source of information about other trials in Italy is given by the Italian Government [4-6]. In
[7], we listed the drugs used in Italy. There we mentioned Tocilizumab, Sarilumab, Siltuximab,
Canakinumab,  Baricitinib,  Methylprednisolone,  Selinexor,  Hydroxychloroquine,  Enoxaparin
sodium,  Solnatide,   Colchicine,   Emapalumab,  Anakinra,  Remdesivir,  Camostat,  Nafamostat,
Ivermectin. 
In Refs. [8-22], some publications related to tocilizumab are given. In [23], a study is proposed. The
research showed that prolonged treatment with tocilizumab has been associated with cases of severe
hepatotoxicity  with  liver  failure  and  hepatitis,  characterised  by  elevated  hepatic  transaminases
(GOT/AST and GPT/ALT). In the case of Covid-19, the treatment is not prolonged.
Cytokine
"Cytokines are a broad and loose category of small proteins important in cell signaling. Cytokines
are peptides and cannot cross the lipid bilayer of cells to enter the cytoplasm. Cytokines have been
shown to be involved in autocrine, paracrine and endocrine signaling as immunomodulating agents.
Their  definite  distinction  from  hormones  is  still  part  of  ongoing  research.  Cytokines  include
chemokines, interferons, interleukins, lymphokines, and tumour necrosis factors, but generally not
hormones or growth factors (despite some overlap in the terminology). Cytokines are produced by a
broad range of cells, ... They act through cell surface receptors and are especially important in the
immune  system;  cytokines  modulate  the  balance  between  humoral  and  cell-based  immune
responses,  and  they  regulate  the  maturation,  growth,  and  responsiveness  of  particular  cell
populations.  Some cytokines enhance or inhibit  the action of other cytokines in complex ways.
They are different from hormones, ...  Cytokines are important in health and disease, specifically in
host immune responses to infection, inflammation, trauma, sepsis, cancer, and reproduction. The
word  comes  from Greek:  cyto,  from Greek  "κύτος"  kytos  "cavity,  cell"  +  kines,  from Greek
"κίνησις" kinēsis "movement"." https://en.wikipedia.org/wiki/Cytokine
Cytokine storm
"Cytokines are small proteins released by many different cells in the body, including those of the
immune  system  where  they  coordinate  the  body’s  response  against  infection  and  trigger
inflammation. ... Sometimes the body’s response to infection can go into overdrive. For example,
when SARS -CoV-2 – the virus behind the covid-19 pandemic – enters the lungs, it triggers an
immune response, attracting immune cells to the region to attack the virus, resulting in localised
inflammation." When it happens that excessive or uncontrolled levels of cytokines are released,
with a consequent activation of more immune cells, the body suffers a hyperinflammation, that is, a
"cytokine storm". 
"Cytokine storms are a common complication not only of covid-19 and flu but of other respiratory
diseases caused by coronaviruses such as SARS and MERS. They are also associated with non-
infectious  diseases  such  as  multiple  sclerosis  and  pancreatitis.  The  phenomenon  became  more
widely known after the 2005 outbreak of the avian H5N1 influenza virus, also known as “bird flu”,
when the high fatality rate was linked to an out-of-control cytokine response."
From "Cytokine storm - An overreaction of the body's immune system", by Alison George, New
Scientist, https://www.newscientist.com/term/cytokine-storm/
"Cytokine storms are associated with a wide variety of infectious and noninfectious diseases. The
term was popularized largely in the context of avian H5N1 influenza virus infection, bringing the
term into popular media" [24]. 
Interleukin-6
"Interleukin 6 (IL-6) is an interleukin that acts as both a pro-inflammatory cytokine and an anti-
inflammatory myokine. In humans, it is encoded by the IL6 gene. In addition, osteoblasts secrete
IL-6 to stimulate osteoclast  formation.  Smooth muscle cells in the tunica media of many blood
vessels  also  produce  IL-6  as  a  pro-inflammatory  cytokine.  IL-6's  role  as  an  anti-inflammatory
myokine is mediated through its inhibitory effects on TNF-alpha and IL-1, and activation of IL-1ra
and IL-10. There is some early evidence that IL-6 can be used as an inflammatory marker for severe
COVID-19 infection with poor prognosis, in the context of the wider coronavirus pandemic. ... IL-6
stimulates  the  inflammatory  and  auto-immune  processes  in  many  diseases  such  as  diabetes,
atherosclerosis, depression, Alzheimer's Disease, systemic lupus erythematosus, multiple myeloma,
prostate cancer, Behçet's disease, and rheumatoid arthritis. Hence, there is an interest in developing
anti-IL-6 agents as therapy against many of these diseases. The first such is tocilizumab, which has
been  approved  for  rheumatoid  arthritis,  Castleman's  disease  and  systemic  juvenile  idiopathic
arthritis.  Others  are  in  clinical  trials.  ...  The  first  FDA  approved  anti-IL-6  treatment  was  for
rheumatoid arthritis." See https://en.wikipedia.org/wiki/Interleukin_6 and references therein.
Drugs used in Italy 
As shown in [7], drugs used in Italy against Covid-19, are targeting cytokines.
"Tocilizumab, also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of
rheumatoid arthritis ... . It is a humanized monoclonal antibody against the interleukin-6 receptor
(IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is
implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma
and  prostate  cancer".  https://en.wikipedia.org/wiki/Tocilizumab  -  Seee  also  "Tocilizumab"
https://www.drugs.com/monograph/tocilizumab.html  -  "Atlizumab:  anti-IL-6  receptor  antibody-
Chugai, anti-interleukin-6 receptor antibody-Chugai, MRA-Chugai". BioDrugs. 2003;17(5):369-72.
https://www.ncbi.nlm.nih.gov/pubmed/14498766  -  "Actemra/RoActemra  (tocilizumab)"  Roche
https://www.roche.com/products/product-details.htm?productId=42bf9d08-8573-491a-944a-
fdbc030ec44b -  "Tocilizumab" by Adith Venkiteshwaran. MAbs. 2009 Sep-Oct;  1(5):  432–438.
doi: 10.4161/mabs.1.5.9497. PMCID: PMC2759492 PMID: 20065633
"Sarilumab  (trade  name  Kevzara)  is  a  human  monoclonal  antibody  against  the  interleukin-6
receptor. ... US FDA approval on 22 May 2017 and European Medicines Agency approval on 23
June 2017." https://en.wikipedia.org/wiki/Sarilumab. "Sarilumab enters clinical trial for COVID-19,
spotlighting 'key role' for IL-6". March 19, 2020. http://archive.is/PFldw "Sarilumab (Kevzara) —
jointly developed Regeneron and Sanofi — is a fully human, monoclonal antibody that inhibits the
interleukin-6  (IL-6)  pathway  by  binding  and  blocking  the  IL-6  receptor.  According  to  the
pharmaceutical  companies’  joint  statement,  IL-6  may  play  a  role  in  driving  the  overactive
inflammatory response in the lungs of patients who are severely or critically ill with COVID-19." 
"Siltuximab (INN, trade name Sylvant; also known as CNTO 328, anti-IL-6 chimeric monoclonal
antibody or cCLB8) is a chimeric (made from human and mouse proteins) monoclonal antibody. It
binds to interleukin-6. Siltuximab has been investigated for the treatment of neoplastic diseases."
https://en.wikipedia.org/wiki/Siltuximab -  "Il  Siltuximab è un anticorpo monoclonale  che agisce
sull'IL-6, è studiato come antitumorale. E' commercializzato come Sylvant; noto anche come CNTO
328. E' studiato per il trattamento di tumori metastatici come il carcinoma a cellule renali, tumore
alla  prostata,  e  per  la  malattia  di  Castleman,  tra  altri  tipi  di  tumore."
https://it.wikipedia.org/wiki/Siltuximab -  "Sylvant  è un medicinale  contenente il  principio attivo
siltuximab." https://www.my-personaltrainer.it/farmaci/sylvant.html
"Canakinumab (INN, trade name Ilaris,  previously ACZ885) is  a human monoclonal  antibody
targeted  at  interleukin-1  beta.  Canakinumab  was  approved  for  the  treatment  of  cryopyrin-
associated periodic syndromes (CAPS) by the U.S. Food and Drug Administration (FDA) in June
2009 and by the European Medicines Agency in October 2009. CAPS is a spectrum of several
autoinflammatory syndromes. ...  Canakinumab was being developed by Novartis for the treatment
of rheumatoid arthritis, but this trial was completed in October 2009. Canakinumab is also in phase
I  clinical  trials  as  a  possible  treatment  for  chronic  obstructive  pulmonary  disease,  gout,  and
coronary artery disease." https://en.wikipedia.org/wiki/Canakinumab
"Baricitinib, sold under the brand name Olumiant among others, is a drug for the treatment of
rheumatoid arthritis (RA) in adults whose disease was not well controlled using RA medications
called  tumor necrosis factor (TNF) antagonists. It acts as an inhibitor of janus kinase (JAK),
blocking the subtypes JAK1 and JAK2." https://en.wikipedia.org/wiki/Baricitinib - About TNF, see
the discussion "In the Lancet".
Other drugs are used in Italy, see [7].
In the Lancet
In "The Lancet",  "The Lancet  Rheumatology",  we find discussed the cytokine  storm syndrome
related to Covid-19, such as in Ref.25. 
In [26], it is told that "SARS-CoV-2-induced pneumonia is marked by hyperactivation of effector T
cells and excessive production of inflammatory cytokines, particularly IL-6. This reaction, known
as a cytokine storm, was initially described as a life-threatening complication in patients receiving
antibody-based  immune  therapy.  In  addition  to  IL-6,  other  cytokines  (ie,  IL-1,  TNF,  and
interferon-γ),  which are produced during the cytokine storm, contribute  to  the pathological
process  that  leads  to  plasma leakage,  vascular  permeability,  and disseminated intravascular
coagulation. ...  In the case of viral infection, these events increase dissemination of the virus, ...  In
line with these events, blockade of IL-6 function with a monoclonal antibody against its receptor
(eg, tocilizumab) is useful for the initial treatment of patients with a so-called cytokine storm,  and
preliminary evidence suggests that such a therapy can help to prevent the detrimental inflammatory
response in some cases of SARS-CoV-2-induced pneumonia (unpublished)".
In [27] it is told that "Cytokine upregulation is documented in COVID-19. In patients with COVID-
19, there is upregulation of pro-inflammatory cytokines in the blood, including interleukin (IL)-1,
IL-6, TNF, and interferon γ, and patients in intensive care units have increased concentrations of
many cytokines. Preliminary data from Salford Royal Hospital and the University of Manchester in
the UK document the presence of proliferating excess monocytes expressing TNF by intracellular
staining in patients with COVID-19 in intensive care (Hussell T, Grainger J, Menon M, Mann E,
University of Manchester, Manchester, UK, personal communication). ... Initial reports comprising
a trial of 21 severe and critical COVID-19 patients in China (ChiCTR2000029765) and a case study
from France [28] of clinical benefit with the anti-IL6 receptor antibody10 tocilizumab in COVID-
19 suggest that cytokines are of importance in the “cytokine storm” and further controlled clinical
trials are in progress. Although there are many potential drug candidates for reducing inflammation
in COVID-19, only a few drugs such as the anti-TNF antibodies infliximab or adalimumab are
potentially effective, widely available, and have a well established safety profile. The potential role
of anti-TNF therapy thus warrants consideration". 
In  [29],  the  author  is  discussing  [27],  where  it  is  suggested  the  potential  use  "of  anti-tumor
necrosis  factor  (TNF) therapy  to  inhibit  development  of  a  cytokine  storm  in  patients  with
coronavirus disease 2019 (COVID-19). Following this Comment," David J M Wright writes "to
propose that the opioid, meptazinol, might be a possible alternative or addition to anti-TNF therapy,
particularly in the UK, where meptazinol is a licensed drug (current licenced supplier Almirall,
Barcelona, Spain) and thus could be easily prescribed." The basis of his suggestion is [30]. 
TNF and TNF inhibitors
"TNF  inhibitors  are  drugs  that  help  stop  inflammation.  They're  used  to  treat  diseases  like
rheumatoid  arthritis  (RA),  juvenile  arthritis,  psoriatic  arthritis,  plaque  psoriasis,  ankylosing
spondylitis, ulcerative colitis (UC), and Crohn's disease. They're also called TNF blockers, biologic
therapies, or anti-TNF drugs. ... TNF inhibitors are antibodies made in a lab from human or animal
tissue. ... Your immune system makes a substance called tumor necrosis factor (TNF). Usually, your
body keeps your TNF levels steady. But if you have an autoimmune disease like RA, something
goes wrong. You start making too much TNF, and that leads to inflammation. ... Because TNF
inhibitors tamp down your immune system to stop inflammation, they can make it harder for you to
fight off infections. You may be at higher risk for getting colds, flu, urinary tract infections, or even
tuberculosis (TB)". https://www.webmd.com/rheumatoid-arthritis/tnf-inhibitor-inflammation#1
"Tumor necrosis factor (TNF) is a multifunctional cytokine that plays important roles in diverse
cellular events such as cell survival, proliferation, differentiation, and death. As a pro-inflammatory
cytokine,  TNF  is  secreted  by  inflammatory  cells,  which  may  be  involved  in  inflammation-
associated carcinogenesis." [31].  
"Tumor necrosis factor (TNF) is a critical cytokine, which contributes to both physiological and
pathological processes." [32]. This reference "will briefly touch the history of TNF discovery, its
family members and its biological and pathological functions".
Potential therapeutic candidates
In [33], we find a work which is summarizing "the current potential  therapeutic approaches for
diseases  related  to  COVID-19  infection  and introduce  their  mechanisms  of  action,  safety,  and
effectiveness". Keywords are "ACE2 blocker, Antimalaria, Antiviral, Chinese traditional medicine,
COVID-19, Immunoenhancer, Monoclonal antibody, Vaccine". "SARS-CoV-2 binds to the ACE2
receptor on the surface of cells using the Spike protein, which subsequently triggers endocytosis".
ACE2  is  the  angiotensin-converting  enzyme  2,  an  enzyme  attached  to  the  outer  surface  (cell
membranes) of cells in the lungs, arteries, heart, kidney, and intestines.
In [33] tocilizumab (TCZ) and sarilumab are considered. TCZ and sarilumab efficiently inhibit IL-6
through both membrane-bound and soluble IL-6R. "TCZ has been approved by the FDA for treating
cytokine release syndrome marked by excessive cytokine production ... COVID-19 disease severity
depends on the increase in pro-inflammatory factors [IL-6, IL-1, IL-2, IL-7, IL-10, granulocyte-
colony stimulating factor, interferon-γ-inducible protein 10, monocyte chemoattractant protein 1,
macrophage inflammatory protein-1 alpha, and TNF-α] (Huang et al., 2020, Ruan et al., 2020, Zhou
et al., 2020a), suggesting that cytokine storms are involved in the development of COVID-19".
In [33] it is also told that "Hydroxychloroquine sulfate (HCQ) shares a similar chemical structure
and mechanisms of action with CQ [Chloroquine] but with lower ocular toxicity (Lim et al., 2009)
and has proven efficacious in containing SARS-CoV-2 in vitro (Liu et al., 2020a). CQ and HCQ
exert  antiviral  function  through various  mechanisms.  CQ has  been shown to interfere  with the
glycosylation process of ACE2 in host cells, thereby inhibiting the efficiency of the binding of S
protein with ACE2, in turn disrupting the virus/cell fusion process (Savarino et al., 2006). CQ can
increase the pH of acidic cellular organelles required for virus entry into host cells (Savarino et al.,
2003). In addition to its direct antiviral activity, CQ and HCQ can attenuate major “cytokine
storms”  (an  overreaction  of  the  immune  system  causing  inflammatory  “storms”)  by
decreasing cytokine production (interleukin [IL]-1, IL-6, and tumor necrosis factor [TNF],
etc.) (van den Borne et al., 1997 [34]). ... the immune-modulating activity of HCQ might partially
account for its efficient control of SARS-CoV-2 infection. CQ and HCQ are therefore promising
drugs of choice for large-scale use due to their low cost, ... . CQ and HCQ need to be administered
with caution when treating COVID-19 infection to prevent toxicity".
Also the Traditional Chinese Medicine (TCM) is proposed, and that " the integration of traditional
Chinese  and  western  medicine  is  a  unique  scheme  in  China.  Approximately  85% of  Chinese
COVID-19 patients  underwent  TCM treatment  as reported by XuNanping,  the vice  minister  of
Science and Technology of China (China's State Council, 2020). In clinical practice, several kinds
of TCM have demonstrated their beneficial effects in treating patients with COVID-19 pneumonia
(Ren et al., 2020). Lianhua Qingwen (LHQW) has a broad-spectrum antiviral effect on a host of
influenza viruses, such as influenza A (H1N1), and HPAI A (H7N9) viruses, by inhibiting viral
propagation and regulating immune function (Ding et al., 2017, Dong et al., 2014). LHQW has been
commonly used for treating viral influenza clinically and played a key role in controlling SARS-
CoV during the 2003 outbreak. Recently, LHQW was reported to have inhibitory activity against
SARS-CoV-2 and anti-inflammatory effects in vitro (Table 1) (Runfeng et al., 2020).  Xuebijing
(whose chemical composition includes safflower yellow A, paginin, ferulic acid, and salvianolic
acid B) functions as an endotoxin antagonist, anti-inflammatory agent, and anticoagulant (He et al.,
2013, Sun et al., 2010, Xu et al., 2009, Zhang et al., 2006) ... A clinical trial showed that injecting
Xuebijing improved the symptoms of severe pneumonia (Wang et al., 2016). Given the cytokine
storms in severe COVID-19 infection, administering Xuebijing could turn critically ill cases into
mild  ones  by  attenuating  the  overactivated  immune  responses  and  preventing  progressive
pathological deterioration. Two clinical trials aimed at testing the efficacy and safety of Xuebijing
injection  for  COVID-19  have  been  registered  in  the  Chinese  Clinical  Trial  Registry
(ChiCTR2000030388 and ChiCTR2000029381)".
What are the components of Lianhua-Qingwen, for instance?
In [35],  we find that  Lianhua-Qingwen capsule (LQC) is  a "commonly used Chinese medical
preparation to treat viral influenza and especially played a very important role in the fight against
severe acute  respiratory syndrome (SARS) in 2002-2003 in China".  After  analysis,  the authors
found  "A  total  of  61  compounds  including  flavonoids,  phenylpropanoids,  anthraquinones,
triterpenoids, iridoids, and other types of compounds were unambiguously or tentatively identified
by comparing the retention times and accurate mass measurement with reference compounds or
literature data. Among them, twelve representative compounds were further quantified as chemical
markers  in  quantitative  analysis,  including  salidroside,  chlorogenic  acid,  forsythoside  E,
cryptochlorogenic acid, amygdalin, sweroside, hyperin, rutin, forsythoside A, phillyrin, rhein, and
glycyrrhizic acid". 
Other proposals
In [36], melatonin as a potential adjuvant treatment is proposed. "Melatonin, - it is told in [36] - a
well-known  anti-inflammatory  and  anti-oxidative  molecule,  is  protective  against  ALI/ARDS1
caused by viral and other pathogens. Melatonin is effective in critical care patients by reducing
vessel permeability,  anxiety,  sedation use, and improving sleeping quality,  which might also be
beneficial for better clinical outcomes for COVID-19 patients. Notably, melatonin has a high safety
profile. There is significant data showing that melatonin limits virus-related diseases and would also
likely be beneficial in COVID-19 patients. Additional experiments and clinical studies are required
to  confirm  this  speculation."  Melatonin  is  also  mentioned  in  [37],  where  it  is  reviewed  "the
melatonergic pathway role in viral infections, emphasizing influenza and covid‐19 infections. Viral,
or preexistent, suppression of pineal melatonin disinhibits neutrophil attraction, thereby contributing
to an initial “cytokine storm”, as well as the regulation of other immune cells". 
"Melatonin is a hormone that regulates the sleep–wake cycle.  ...  While it is known that melatonin
interacts with the immune system, the details of those interactions are unclear. An antiinflammatory
effect seems to be the most relevant. There have been few trials designed to judge the effectiveness
of melatonin in disease treatment. Most existing data are based on small, incomplete trials. Any
positive  immunological  effect  is  thought  to  be  the  result  of  melatonin  acting  on  high-affinity
receptors (MT1 and MT2) expressed in immunocompetent cells. In preclinical studies, melatonin
may enhance cytokine production (Wikipedia gives reference [38], and by doing this, counteract
acquired immunodeficiences.  Some studies also suggest that melatonin might be useful fighting
infectious  disease  including  viral,  such as  HIV,  and bacterial  infections,  and potentially  in  the
treatment of cancer."  https://en.wikipedia.org/wiki/Melatonin
Of course, it is necessary to investigate the cytokines on which melatonin is acting. In [39], it is told
that  "The  report  shows  that  melatonin  enhances  IL‐2  and  IL‐6  production  by  two  human
lymphocytic (Jurkat) and monocytic (U937) cell lines via a nuclear receptor‐mediated mechanism". 
Vitamin D
In [33], it is told that "Lopinavir/ritonavir and favipiravir inhibit the proteolysis of polypeptide
chains.  Remdesivir inhibits RNA-dependent RNA polymerase.  EIDD-2801 could inhibit SARS-
CoV-2 replication. NO and Zinc might inhibit SARS-CoV-2 replication. Vitamin D might induce
antimicrobial  peptides  to  reduce  SARS-CoV-2  replication.  Ivermectin could  effectively  block
SARS-CoV-2  growth.  Baricitinib could  interrupt  the  passage  of  SARS-CoV-2  entering  cells
through inhibition of AAK1-mediated endocytosis. CQ and HCQ inhibit virus/cell fusion process.
LHQW  and  IFNs  could  block  the  process  of  virus  replication  (RNAs  transcription,  protein
translation, and post-translational modification)". Of Remdesivir, Baricitinib, Hydroxychloroquine
Ivermectin we told in [7].  We find Vitamin D too.
Let me report a part from abstract of [40], entitled "Vitamin D: A simpler alternative to tocilizumab
for  trial  in COVID-19?".  "Like  tocilizumab,  Vitamin D appears  to  modulate  the activity  of an
interleukin  (IL-6),  which  may  explain  the  seasonal  variation  in  prevalence  of  influenza.  ...  A
retrospective  comparison  of  Vitamin  D  levels  in  previously  obtained  blood  samples  between
1 Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS)
survivors  and confirmed fatalities  could  establish  a  rationale  for  implementation  of  widespread
Vitamin  D  supplementation.  This  would  be  far  cheaper  and  simpler  than  tocilizumab  as  a
therapeutic option to trial". In the article it is also written: "given that Vitamin D appears to have
similar modulating effects on an interleukin, it offers a realistic alternative treatment option which
may save many lives." No references are given in [40], about the similar effect on interleukins.
However, studies exist [41-44].
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